Dr. Cha is an Associate Professor in the Department of Neurology with subspeciality training in neurotology. She joined the faculty of the department in July 2019 as a MnDRIVE Scholar to pursue research on the application of non-invasive brain stimulation methods on the modulation of motion perception, treatment of vertigo, and enhancement of gait and balance. She developed the first neuromodulation based clinical trials in a motion entrainment disorder called mal de debarquement syndrome (MdDS) in which individuals who are exposed to passive oscillation, such as on a boat, develop a persistent oscillating vertigo as if they are still on the boat when they return to stable ground. The study of MdDS revealed the importance of brain regions not traditionally thought to be part of the vestibular system in the creation of motion perception. Understanding how motion entrainment can affect multiple resting state brain networks provided insights into why migraine, anxiety, and cognitive dysfunction are frequently comorbid with vestibular disorders. Besides research on the use of non-invasive brain stimulation tools such as transcranial alternating current stimulation and transcranial magnetic stimulation, Dr. Cha sees patients in the neurology clinic with a focus on chronic headache, vertigo, and gait dysfunction.

Dr. Cooper is a clinical neurologist specializing in movement disorders and a research physiologist specializing in control of voluntary movement. His long term goal is to combine the two roles fruitfully. He studies pathophysiology of the extrapyramidal motor system with a particular focus on basal ganglia and Parkinson's disease and on deep brain stimulation. His research is with human subjects and he collaborate extensively with bioengineers, neurosurgeons, and neuropsychologists.

Dr. Cullen is a tenured Associate Professor in the Department of Psychiatry and Behavioral Sciences, and the Director of the Child and Adolescent Psychiatry Division at the University of Minnesota. She completed all of her medical and research training at the University of Minnesota. Dr. Cullen leads an NIH-funded research team examining the neurodevelopmental underpinnings of depression, self-injury and suicide risk in adolescents and young adults, and investigating interventions aimed at promoting healthy trajectories in these youth.

Dr. Darrow is an Assistant Professor in the Department of Neurosurgery, specializing in functional and pain neurosurgery. He treats diseases of the central nervous system including epilepsy, movement disorders, trigeminal neuralgia/facial pain, chronic pain, and psychiatric diseases. Dr. Darrow completed his neurosurgery at the University of Minnesota where he worked on developing novel neuromodulation techniques and applications including focused ultrasound, spinal cord stimulation, peripheral nerve stimulation, and deep brain stimulation. Dr. Darrow is co-PI of the Herman-Darrow Human Neuroscience Lab with a mission of understanding and treating disorders of the nervous system with neuromodulation. The Herman-Darrow Lab links together circuit-level electrophysiology with behavior. By pairing neuromodulation with a quantitative understanding of the pathological circuits of the brain, the lab hopes to help patients improve symptoms and quality of life. Dr. Darrow is the PI for the E-STAND trial, where neuromodulation is used to restore function after Spinal Cord Injury. In collaboration with many other investigators, the team is testing neuromodulation to restore volitional movement and autonomic function using algorithmic, personalized approaches through remote data collection.

Dr. Ebbini's lab is investigating image-guided transcranial application of focused ultrasound (tFUS) to neuromodulation. They have developed a unique paradigm for tFUS utilizing our dual-mode ultrasound array (DMUA) prototypes. DMUAs are capable of subtherapeutic or therapeutic of tFUS while providing real-time monitoring and localization of its interactions with brain tissue. Our DMUA prototypes have been shown to detect and localize both mechanical and thermal tFUS-tissue interactions with brain tissues in a rat model in vivo.

Dr. Engel's lab studies neuroplasticity in the human visual system. He uses environmental manipulations, including augmented reality, to try to modulate function of the visual brain.

Dr. Ghose's lab studies the neurophysiological basis of cognitive factors such as attention and learning which are critical to behavioral performance. They employ neuromodulation and stimulation to understand, probe, and hopefully augment or mimic the effects of these factors. They also use a variety of techniques including multi-electrode recordings, optical imaging, fMRI, computation, and psychophysics to characterize these factors, and their neural bases, in both behaving animals and humans. 

Dr. Harel's current research focuses on the development and integration of 7T MRI and high-field neuroimaging data into deep brain stimulation (DBS) surgical navigation in particular and brain surgery in general. They are developing new structural/anatomical imaging which are combined with post processing image analysis schemes for the creation of a 3-dimensional anatomical model of the brain. This 3D model created by the 7T images allows us to literally ‘see’ the individual shape, size, and orientation of the brain target area for deep brain stimulation (DBS) therapy.

Dr. Herman is an Assistant Professor of Psychiatry at the University of Minnesota Medical School and a member of the Medical Discovery Team on Addiction. Dr. Herman's human neuroscience lab studies neural mechanisms of decision-making that are impaired in addiction and amendable to treatment with neuromodulation. His lab combines invasive and non-invasive methods including intracranial electrophysiology, direct brain stimulation, magnetoencephalography, and transcranial magnetic stimulation. Advanced computational methods are utilized to find underlyning connections between brain activity, stimulation and behavior. Clinically, Dr. Herman is developing a speciality practice in refractory mood and anxiety co-morbid with addiction and chronic pain disorders.

Dr. Johnson’s research addresses critical questions regarding the pathophysiology underlying movement disorders such as Parkinson’s disease (PD) and mechanisms of action of therapeutics such as deep brain stimulation (DBS). He is leveraging this understanding to improve existing treatment options and develop new therapeutic strategies to alleviate motor and non-motor symptoms of PD (e.g. sleep dysfunction). 

Dr. Johnson's lab is primarily interested in developing and refining neural interface technologies to improve the quality of life for people with movement disorders. Deep brain stimulation (DBS) is one such technology, which over the past twenty years has helped numerous patients with Parkinson’s disease, dystonia, and essential tremor reclaim control over their motor function. The therapy involves placing small electrodes in regions of the brain that exhibit pathological activity, which contributes to the movement disorder, and then stimulating those regions with continuous pulses of electricity. His lab focuses on understanding how the brain responds and adapts to such stimulation-based therapies from a combination of computational and experimental perspectives. The knowledge gained from these studies in turn provides us with a framework to develop, evaluate, and translate new approaches for improving patient outcome.

Dr. Kodandaramaiah's research group is focused on engineering neurotechnologies that help better understand how computations that occur in the brain drive behavior. A critical challenge for modern neuroscience is to study neuronal computations across multiple spatial and temporal scales. Traditionally, technologies used to observe activities at one level do not scale to the next level without loss of signal fidelity or information. HIs laboratory is combining expertise in robotics, precision engineering, optics and microfabrication for engineering technologies that seek to bridge these experimental scales.  

Dr. Konczak's research focuses on sensorimotor dysfunction in neurological diseases. His lab is actively engaged in developing new behavioral treatment options that can supplement or augment existing therapies. Currently, are investigating how neuromodulation affects haptic perception in Parkinson's disease and how it changes voice quality for patients with a dystonic voice disorder called, spasmodic dysphonia.

Dr. Kotz's team uses neuromodulation techniques to understand the role of the neurohormone orexin in energy balance. Her laboratory first developed the idea that orexin drives spontaneous physical activity (SPA) and non-exercise activity thermogenesis (NEAT); that it interacts with other neurotransmitters and brain sites in a network fashion; and that it has relevance to obesity: higher orexin signaling is associated with greater SPA and NEAT, the lean state and obesity resistance. Recently they have shown that orexin stimulation - either by direct receptor stimulation with orexin A injections in rats, or by DREADD [Designer Receptors Exclusively Activated by Designer Drugs] stimulation of orexin neurons in mice, prevents diet-induced adiposity and weight gain. This, coupled with our use of optogenetics to understand effects of acute simulation and inhibition of orexin neurons, and the recent development of the CAV2-Cre virus, which transfers Cre recombinase retrogradely between neurons, allows us to begin the study of orexin thermogenic pathways relevant to obesity.   

Neuronal networks, diversity, and specificity of function are important to both physiological processes and neurological disorders, including epilepsy. Dr. Krook-Magnuson's laboratory seeks to improve our understanding of how cells interact within a network, how networks interact with each other, and the physiological roles of neuronal populations. In this regard, key questions remain in epilepsy research, including what are the principal networks, conditions, and cell types involved in initiating, sustaining, propagating, terminating, and potentially suppressing, seizures. By improving our understanding of these, we improve the prospects of someday reaching the goal of no seizures, no side effects, for all epilepsy patients. Her lab uses rodent models of neurological disorders, including temporal lobe epilepsy, and techniques including electrophysiology, optogenetics, immunocytochemistry, transgenic animals, and behavioral experiments to address these fundamental questions.

Dr. Kumar is currently William Norris Professor and Head of the Computer Science and Engineering Department at the University of Minnesota. He's current research interests include data mining, high-performance computing, and their applications in Neuroscience, Climate/Ecosystems and Biomedical domains. In the context of human neuroscience, the focus is on functional connectivity and its dynamics in healthy, disease, and post-treatment conditions. Functional connectivity analysis techniques developed in his group are highly suited for assessing the effectiveness of neuromodulation in treating mental disorders.

Dr. Lim's lab goal is to push the development and translation of neural interfaces and medical technologies from scientific concept into clinical application with close collaboration with clinicians and industry. Initial medical applications focus on treating hearing loss, tinnitus and pain. They utilize a range of invasive and noninvasive technologies and approaches including electrical stimulation, ultrasound imaging and stimulation, EEG, and invasive neural recordings in animals and humans to rapidly push technology into the clinical and consumer realm.

Dr. Lim’s research interest is in the use of neuroimaging approaches to identify circuit abnormalities in brain disorders such as schizophrenia, traumatic brain injury and addiction and then to use these circuits as treatment targets for noninvasive neuromodulation interventions. He is currently conducting studies that combine transcranial direct current stimulation neuromodulation with cognitive training to improve cognition in subjects with schizophrenia, traumatic brain injury, and addiction.

Dr. MacDonald III's laboratory examines cognitive control, working memory, and executive functioning and decision making. They are using neuroimaging to decode brain regions involved in these processes, and transcranial stimulation to examine and promote plasticity in these processes. This work extends into psychopathology, such as understanding how brain stimulation can promote cognitive remediation in people with schizophrenia or predicting decisions related to addiction risk.

Dr. MacKinnon's Movement Disorders Laboratory's mission is to gain a greater understanding of the mechanisms causing movement problems in people with neurological disorders and to translate this knowledge to the development of novel therapies and interventions to improve movement function, mobility, and quality of life. They use a variety of non-invasive neurophysiological techniques (high-resolution EEG, TMS, tDCS, startle) to probe the cortical, subcortical, and spinal mechanisms contributing to movement impairment. They also collaborate with Center of Magnetic Resonance Research (CMRR), to use brain imaging methods to examine the changes in brain anatomy and connectivity associated with movement disorders. Their present research focus is to examine the mechanisms contributing to the motor symptoms of Parkinson's disease and to advance the basic understanding and therapeutic efficacy of deep brain stimulation technology.

Dr. McGovern is a functional/stereotactical neurosurgeon who specializes in treating patients with epilepsy at M Health Fairview Clinics and Surgery Center - Minneapolis and the Minneapolis Veterans Affairs Medical Center. He conducts research on untreatable balance and gait problems in Parkinson’s patients and offers treatments such as deep-brain stimulation for Parkinson's patients and minimally invasive surgery to stop epileptic seizures. 

Dr. Mesce's laboratory is studying how the neuroactive substance, dopamine, influences identifiable neural circuits to choreograph specific locomotor programs, and impacts decision-making processes. To address such issues, at the level of single neurons and their interconnections, we utilize experimentally-tractable invertebrate preparations. Such systems have also proven beneficial for the testing of cutting-edge technologies for brain modulation. Currently, we are designing, manufacturing, and testing novel micro devices for the dual recording of electrical and chemical signals. They are also examining the cellular mechanisms underlying ultrasound neuromodulation.

Dr. Michaeli's research goal is to utilize novel DBS paradigms based on the generation of rotating fields by amplitude and frequency modulated pulses, for efficient low energy modulation of thalamic – cortical pathways. The general objective is to optimize DBS pulse shapes to generate excitation of selective neuronal populations. The work on animal models is critical for the translation of more efficient and safer DBS strategies to humans. Development of novel efficient schemes which allow for flexible and selective excitability of cell’s and axonal populations is critical. The detection of network level activity leaded to a breakthrough development of resting state functional MRI (rsfMRI) methodologies. Their preliminary studies demonstrate that strikingly different functional connectivity outcomes can be robustly measured by fMRI in rest and activated conditions upon different DBS paradigms, thus substantiating the rationale for this project.

Dr. Nahas's scientific interests lie in translational research of mood dysregulation and depressive disorders. His unique expertise is in functional neuroimaging and brain stimulation across various modalities [Transcranial Magnetic Stimulation (TMS), Vagus Nerve Stimulation (VNS), Epidural prefrontal Cortical Stimulation (EpCS), Deep Brain Stimulation (DBS), Electroconvulsive Therapy (ECT) and Focally Electrically Administered Seizure Therapy (FEAST)]. He has also conducted basic research and collaborated on health economic studies. He received funding from various sources, notably the National Institute of Mental Health, National Alliance for Research in Schizophrenia and Depression (NARSAD) and the Hope for Depression Research Foundation (HDRF). 

In the Center for Applied and Translational Sensory Science (CATSS) lab, Dr. Nelson's team is working on the development and refinement of sensory aids for sensory loss. Most of Dr. Nelson’s work is focused on auditory perception and device evaluation. Specifically, they believe that auditory sensory aids (hearing aids and cochlear implants) have progressed to the point where speech intelligibility is conveyed quite successfully, at least for understanding in quiet environments. They believe the next stage is improving the sound quality and ease of listening for users of these sensory aids. Improving these abilities would ensure that the central auditory system has acclimated to the new inputs, and is processing them as natural acoustic information. Visual and vestibular implants are in earlier stages of development, but show promise to improve sensory input to the brain to improve quality of life for millions of Americans.

Dr. Netoff's research laboratory focuses on understanding the basic neuroscience underlying epilepsy and developing new ways to treat epilepsy. Using mathematic analysis to simplify the non-linear and high order activity of the brain into meaningful and more easily understood data. Using the mathematical models they develop, can predict how new drugs will affect brain activity or how deep brain stimulation will alter synchrony in networks. Their goal is to develop new, innovative ways to predict, treat, and terminate seizures to improve patient care. His lab wants to better understand how seizures are generated and how they propagate through the brain. Their research leads to the belief that inhibitory cells may play a significant role in the onset of seizures.

Our laboratory studies the role of the autonomic nervous system​ in the​ pathogenesis of cardiovascular and metabolic diseases with an emphasis on hypertension. We are particularly interested in how nerves to (efferent sympathetic) and from (visceral afferent) the kidney regulate renal and cardiovascular function. At the present time we are developing novel approaches to modulate renal nerves, using optogenetic​s​.

Dr. Park will use his background in biology, medicine, and electrical engineering to work with other university departments, such as neurology and medical bioengineering, to create new devices that increase therapeutic options for patients with brain conditions. His research interests include: brain structure,  neuromodulation/deep brain stimulation, and medical device innovation. 

I am interested in the neural mechanisms associated with the processing of information that leads to the production of movements. For this purpose, we combine psychophysical and neurophysiological approaches. The current projects concern (1) how the brain deals with uncertainty during motor planning; (2) the decoding of brain signals for brain-machine interface applications.

My main research objective is to use theory, neurophysiology, and computational modeling to understand how the brain drives behavior. My lab combines multi-electrode neural ensemble recordings from awake, behaving animals with complex computational analysis techniques that enable measurement of neural dynamics at very fast time scales (e.g. msec).   Furthering the understanding of the neural mechanisms that underlie decision-making allows us to modulate those decision-making processes, behaviorally as well as neurally.

Brain disorders and mental illness represent a tremendous social and economic burden, with few effective treatments. The goal of our research is to identify the causes of brain conditions, and develop interventions to restore healthy function using synaptic plasticity and neuromodulation. We study the striatum, and important brain region for both simple and complex movements and cognitive functions. We examine the function of neural circuits formed by striatal synapses that connect specific sources and targets. Our multidisciplinary approach includes quantitative analysis of gene expression; genetic and molecular manipulations of neural circuits; measurement of synaptic function and plasticity using electrophysiology; and optogenetic stimulation of circuits in brain slices and behaving animals. Our current research focuses on autism spectrum disorders and drug addiction - two brain conditions that affect overlapping elements of striatal circuitry.

I came late to neuromodulation, having been trained as a neuro-oncologist with research interests in quantitative neuroimaging and computational anatomy.  With the advent of deep brain stimulation (DBS) for the treatment of movement disorders in the 1990's I recognized an opportunity to transfer my computer skills and computational interests to programming the implanted pulse generators used for DBS.  My clinical and research interests in DBS focus on the poorly-understood high-dimensional space created by the multiple parameters — active contacts, applied voltage, pulse width, constant current, and stimulation frequency — that are routinely selected to modulate DBS in individual patients.

Our group invents and applies protein engineering technologies to study how cells sense, integrate and exchange information, how pathologic changes in these processes relate to health and disease, and provide insights into new therapies. We are developing novel optogenetic reagents that allow us to systematically perturb specific ion channels and signaling receptors in a time- and amplitude-variant manner. We combine these molecular reagents into an experimental framework in which all families of ion channels and receptors can be independently controlled, and their contribution to diverse cellular signal transduction circuits investigated.

We study the therapeutic effect and efficacy of vagal nerve stimulation (VNS) therapy in experimental in-vivo animal models, aiming to assess the effects of VNS therapy on the functional and electrophysiological properties of the heart. We continuously record in-vivo ECG and blood pressure to characterize the effect of VNS on heart rate, blood pressure and arrythmias. We also perform ex-vivo optical mapping experiments in the isolated whole heart that  allow us to study complex spatio-temporal organization of electrical activity encountered in the heart during normal and abnormal rhythms, and investigate the electrophysiological properties induced by VNS in both healthy and diseased hearts.

As a founding member of the neuromodulation team when I arrived at the University of Minnesota in 1996 I am playing a crucial role in managing the medical aspects related to Parkinson's disease as well as partaking in the Deep Brain Stimulation (DBS) surgical program consensus meetings that help select appropriate individuals for DBS surgery. 

Dr. Ugurbil is the director of the Center for Magnetic Resonance Research (CMRR) where he leads a multi-investigator and multi-disciplinary research effort focused on imaging brain anatomy, function, and connectivity with magnetic resonance (MR) techniques, particularly at ultrahigh (7 Tesla and above) magnetic fields. These techniques are increasingly important in evaluating numerous aspects of neuromodulation, such as defining circuits involved, targets for neuromodulation, consequences of neuromodulation, etc.

Dr. Sophia Vinogradov directs a translational clinical neuroscience laboratory that focuses on cognitive dysfunction in psychosis. The lab studies neuroscience-informed cognitive training methods and seeks to understand the mechanisms that drive enduring plastic changes in cortical and subcortical processing. Her team uses MEG, EEG, and fMRI methods to probe brain changes in both early sensory processing and higher-order cognitive operations in people who undergo this kind of cognitive training. There is a large focus on studying young adults in early psychosis, with the goal of ameliorating cognition and delaying or preventing the onset of a deteriorating psychiatric illness. Her work has contributed to a growing interest in the use of computerized “brain training” to treat some of the brain information processing abnormalities of psychiatric illnesses. She was a participant at the White House conference on “Video Games to Enhance Attention and Well-Being,” and a recipient of the NAMI National Research Award.

Dr. Vitek directs a large interdisciplinary neuromodulation research program primarily centered on understanding the pathophysiology of movement disorders such as Parkinson's disease and dystonia as well as the mechanisms underlying the therapeutic effect of deep brain stimulation. Dr. Vitek serves as the principal investigator for both pre-clinical laboratory studies using animal models and clinical studies on human subjects/patients. Much of his work focuses on the ultimate translation of basic laboratory research discoveries into clinical treatment options for affected patients in order to reduce symptoms, minimize side effects and enhance function and quality of life. Dr. Vitek forms key collaborations with other experts in neurology as well as other disciplines such as neurosurgery, neuroscience, biomedical science, and radiology in addition to the medical industry to expedite and enhance new discoveries and their meaningful translation from “bench to bedside.

Dr. Widge is a brain stimulation psychiatrist and biomedical engineer. He leads the Translational NeuroEngineering Lab, which develops new brain stimulation treatments for severe and treatment-resistant mental illness. The lab's work includes a variety of new algorithms for closed-loop brain stimulation and stimulation methods for modifying connectivity in the distributed circuits of mental illness. Studies cover the full translational range, from rodents to non-human primates to humans in clinical trials.

Zhi Yang is an Assistant Professor at the Department of Biomedical Engineering at the University of Minnesota. He is the PI of the NeuroElectronics Lab, working on new stimulation, recording, and signal processing device that can enable high channel counts and closed-loop neuromodulation in the brain and in peripheral/autonomic nerves.